You are here: Industry Insights > Market News > NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

TAYACN Drying Ammonium thiocyanate ZLG series vibration fluidized bed dryer

TAYACN Drying Nickel chloride water ZLG series vibration fluidized bed dryer

TAYACN Drying Flavoring ZLG series vibration fluidized bed dryer

TAYACN Drying Resin ZLG series vibration fluidized bed dryer

TAYACN Drying Thiourea particles ZLG series vibration fluidized bed dryer

TAYACN Drying Sodium percarbonate ZLG series vibration fluidized bed dryer

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

October 25, 2021

Tag: NMPA , drug regulatory , products

Favorites

The National Medical Products Administration (NMPA) issued a list of the second group of key projects for China's drug regulatory science action plan based on the summary of the implementation of the first group on June 24.

Departments and related affiliated institutions of the NMPA were urged to speedily formulate implementation plans in accordance with related requirements and to further improve their drug regulatory capacities, so as to speed up the marketization of innovative products and better meet the needs of public health.

Previous:Emergency Physicians: We Must Address Vaccine Hesitancy, Correct Misinformation to End Pandemic

Next:Phlow receives approval to join BARDA CDMO network

Alzheimer’s Disease: Charting the Course from Plaques to Promise

Muhammad Farhan KhalidMay 28, 2025

New Tools，New Hope，New Frontier

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

PharmaSourcesMay 16, 2025

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

PR NewswireMay 12, 2025

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan | Pharmasources.com

Illuccix China Phase 3 Study Completes Enrolment

PR NewswireMay 13, 2025

Telix Pharmaceuticals Limited announces that the pivotal Phase 3 registration study of TLX591-CDx for prostate cancer imaging in Chinese patients has completed patient enrolment.

You may like
More>>

PET bottle for health products

A variety of plastic products, blister packaging boxes, plastic trays, food trays, electronic trays

Hot selling top quality health products Echinacea extract Chicoric Acid

Dairy products Improver

Coater And Its Products

Cosmetics Grade Kojic Acid Dipalmitate PowderHot sale products

Electronic hardware plastic tray container specializing in the production of plastic products 21 pil

biological products vegetable protein instant solid beverage Wheat extract milk spray drying machine

Other anesthesia products

Tray Dryers for Drying Seeds & Agro Products

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may like
More>>

free性video西欧极品,伊人依成久久人综合网,中文字幕人妻一区二区三区熟女,男女高潮激烈无遮挡免费观软件 ,成人3d动漫一区二区三区

NMPA releases 2nd group of key projects for China’s drug regulatory science action plan

Related News

Alzheimer’s Disease: Charting the Course from Plaques to Promise

InnoCare Announces First Patient Dosed in the Phase II/IIII Clinical Trial of TYK2 Inhibitor Soficitinib for Treatment of Vitiligo in China

The Phase 3 Clinical Trial of Disitamab Vedotin as a First-Line Therapy for HER2-Expressing Locally Advanced or Metastatic ?Urothelial Carcinoma Reached its Primary Endpoints of PFS and OS

Illuccix China Phase 3 Study Completes Enrolment

You may likeMore>>

You may like
More>>